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Abstract
Antimicrobial resistance (AMR) and its relevant health consequences have been 
explicitly framed as a shared global problem and are estimated to be one of the 
largest causes of death worldwide by 2050. Antimicrobial photodynamic therapy 
(aPDT) proposes an alternative treatment for localized infections in response to 
AMR’s ever-growing problem. This technique combines molecular oxygen, a non-
toxic photoactivatable photosensitizer (PS), and light of appropriate wavelength, 
leading to the formation of cytotoxic reactive oxygen species. Besides the ability 
to inactivate resistant pathogens via a non-selective approach (multiple targets), a 
relevant advantage of aPDT resides in the fact that no evidence of microorganism 
resistance has ever been reported to it. In this chapter, we address some efforts to 
use this technology to kill bacteria in the respiratory tract, from in vitro to clinical 
applications. We put forward three focuses: pharyngotonsillitis, pneumonia, and 
preventing secondary infections during the use of a photosensitizer-functionalized 
endotracheal tube. The results here presented offer a foundation for what may 
become a much larger clinical approach to treat respiratory tract infections.
Keywords: antimicrobial resistance, antimicrobial photodynamic therapy, 
photochemotherapy, infections of the respiratory tract, endotracheal tube
1. Introduction
The increasing use of antibiotics has an important impact on human health by 
introducing the emergence of resistant bacterial strains, both in humans treated in 
an indiscriminate manner, and in two other situations as worrying as, which are the 
presence of these molecules in drinking water and abusive use in agriculture. This 
has all resulted in the phenomenon of antimicrobial resistance (AMR) [1].
Each year worldwide, 700,000 deaths occur, approximately, due to diseases that 
had antimicrobial resistance as responsible for the deaths. By 2050, these deaths 
could reach the terrifying 10 million mark [1].
One of the biggest barriers to antibiotic-resistant infections is that they add 
significant costs to the any nation’s already overburdened health system [2].
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Thus, the paths have been opened for other ways to fight infections and photo-
dynamic therapy (PDT) has stood out with the aim of inactivating not only bacte-
ria, but also fungi, protozoa, and viruses. It is a promising technique, including the 
treatment of diseases that already have antimicrobial resistance.
In this chapter we will address the theme of advances in research  involving 
microbiological control with photodynamic action, more specifically in the 
 treatment or prevention of diseases of the respiratory tract.
1.1 Antimicrobial resistance
The bacteria have developed several mechanisms to fight against  antibiotics 
action. An important molecular mechanism involves the horizontal transfer of 
genes from the efflux pumps when the organism acquires a gene that confers 
the ability to eliminate antibiotics from the intracellular environment [3]. A 
well-known example is the acquisition of the β-lactamase gene from antibiotic 
inactivating enzymes, which inactivates β-lactam antibiotics, such as penicillin 
and cephalosporins [3], where bacteria acquire the ability to inactivate antibiotics 
through an enzymatic mechanism.
Two interesting aspects are related to cell wall morphology and the ability of 
bacterial colonies to form biofilms, and interestingly, these aspects are directly 
related to the cell wall structure of Gram-positive bacteria. The cell-wall glycopoly-
mers from Gram-positive bacteria present an essential role in host-cell adhesion, the 
first step towards forming a bacterial biofilm. In contrast to Gram-negative, Gram-
positive bacteria have a thicker cell wall structure with multiple layers of peptido-
glycan. In addition, many Gram-positive bacteria have protective surface structures, 
typically with glycopolymers bound to peptidoglycan or membrane lipids. These 
structures include glycopolymers of teicoic acids and branched mycobacterial 
polymers [4]. Infections caused by Gram-positive bacteria are important for human 
health and it is worrying that these bacteria are becoming increasingly resistant to 
existing antibiotics. The teicoic acids wall has multiple functional roles in Gram-
positive bacteria including resistance to cationic antimicrobial peptides, such as 
the vancomycin, a glycopeptide antibiotic. Other cellular processes influenced by 
this wall include autolysis, cell division, the location of penicillin-binding protein, 
survival at higher temperatures, biofilm formation and epithelial cell adhesion [5].
Biofilms have an important impact on bacterial infections and also on bacte-
rial resistance. Organisms structured in biofilms exhibit up to 1,000 times more 
resistance to antibiotics than planktonic cells.
1.2 Mechanisms of antibiotic resistance
Pathogenic bacteria resistant to antibiotics are prevalent in different popula-
tions of the environment such as from the soil and water containing encode genes 
with resistance mechanisms [6], which can be mobilized for new hosts, including 
humans [7] and, depending on genic expression, may result in significant public 
health problems [8]. If the microbial mutations are for its benefice, such as antibi-
otic resistance, they are predominant in the species and transmitted for subsequent 
generations, making the bacteria predominant antibiotic-resistant [9]. The mecha-
nisms of an antimicrobial resistance may be intrinsic to the microorganisms or even 
acquired through the transmission of the genetic material or by mutation (which 
may occur during replication) during the bacterial evolution, whether induced or 
spontaneous, by mutation mechanisms in a chromosome or transfer genes loci, 
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which can encode inactivate enzymes in antibiotics or even reducing their perme-
ability in cells [10]. The bacterial mutations that can occur are replacement (transi-
tion and transversion); deletion (macrodelection and microdeletion); insertion 
(macroinsertion and microinsection) and inversion, with exchange of pyrimidine 
or purine, removal of nucleotides, the inclusion of nucleotides, and removal or 
insertion of DNA, respectively.
Strains resistant to antibiotics can be transmitted between patients in healthcare 
units, often through healthcare professionals’ contaminated hands, medical-surgi-
cal equipment, or inanimate objects from the hospital environment [11]. This type 
of spread is generally clonal, involving the transmission of a single resistant strain. 
Outbreaks caused by the clonal spread of an antibiotic-resistant organism have 
been commonly reported in S. aureus MRSA strains [12]. Patients’ transmission can 
be clonal in multiple species of strains with different prevalence according to the 
geographic region [13].
1.3 The worldwide impact of antimicrobial resistance
Infectious diseases are a major cause of human deaths. According to the World 
Health Organization (WHO), on the top ten global causes of death (2016), chronic 
obstructive pulmonary disease and lower respiratory infections are occupying the 
third and fourth places, respectively, behind ischemic heart disease and stroke 
[14]. It is relevant to note that infectious diseases outperform all types of cancer 
in terms of mortality, according to WHO data. Figures reported in 2016 indicate 
that there were 3.190 million deaths due to respiratory infections, with a mortality 
rate of 43/100,000. Analyzing again the top ten global causes of death but now, in 
low-income countries (2016), lower respiratory infections were among the leading 
causes of death across all income groups [14].
It is essential to discover and invest in the development of new antibiotic 
molecules, following the growing global need. But just as importantly, research into 
new non-antibiotic approaches for the prevention and protection against infec-
tious diseases is needed and should be encouraged and a high priority research and 
development project [15].
In the US, the Centers for Disease Control and Prevention (CDC) estimated that 
antibiotic-resistant infections are responsible for $20 billion a year in additional 
health care costs, and $35 billion a due to loss of productivity [16]. Thus, a deeper 
understanding of the mechanisms of resistance to antibiotics is relevant in terms 
of human health, that is, it saves human lives, but it also reduces an important 
 economic burden for public and private health systems.
Penicillin, discovered by Fleming in 1928, was first tested for the treatment 
of infectious diseases in the 1930s and became a widespread drug in the 1940s. 
β-lactam antibiotics, the group to which penicillin belongs, are effectively drugs 
of choice for the treatment of community-based respiratory diseases, for example, 
which are usually caused by Gram-positive bacteria, such as Staphylococcus and 
Streptococcus.
The introduction of new antibiotics in clinical use was quickly followed by the 
clinical observation of resistant strains and the time between clinical use and resis-
tance has become shorter and shorter. For example, sulfonamides were introduced 
for clinical use in 1930 and resistant strains appeared in the 1940s. Vancomycin was 
introduced in 1956 and resistant strains were first reported in 1988. However, for 
newer antibiotics, such as daptomycin, fidaxomycin and linezolid, resistance was 
observed in the same year in which clinical use began [17].
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2. Antimicrobial photodynamic therapy (aPDT)
The mechanisms of aPDT are basically the same of PDT for tumors, based on the 
combined action of three elements: a photosensitizer (PS), a light source at appro-
priate wavelength to excite the PS and molecular oxygen (O2) in the target tissue.
The photodynamic process inactivating microorganisms occurs through the 
action of reactive oxygen species (ROS) that destroy vital constituents of fungi, 
bacteria, viruses and protozoa. In 1933 Jablonski published his article explaining 
the electronic states of a molecule and the transitions between them [18]. In this 
famous “Jablonski’s diagram”, we understand how a photosensitizer in the singlet 
ground state, moves to the excited singlet state after absorbing photons from a light 
source. And through the process named “intersystem crossing”, a spin inversion 
occurs and then, this molecule goes to the excited triplet state, giving it conditions 
to transfer energy (type II mechanism) or electron (type I mechanism) to O2, 
generating ROS.
For antimicrobial purposes, the photodynamic action will take place within the 
cells or at the extracellular matrix of the microbial biofilm where the photosensi-
tizer molecules are present, the main sites being the outer membrane or cell wall, 
membrane lipids and lipopolysaccharides. The singlet oxygen produced has a very 
small radius of action, less than 0.02 μm, so the damage produced by PDT will only 
be in the presence of the photosensitizer and under photoactivation. As a result, 
cell death is caused by cell wall or membrane lysis and/or inactivation of proteins or 
enzymes essential for microbial metabolism [19].
3. aPDT of respiratory tract diseases
3.1 Pharyngotonsillitis
Sore throat is a frequent complaint in outpatient medical consultations and 
emergencies. Acute pharyngotonsillitis represents a significant source of social 
disorders in the child population, such as missed classes repeated use of antimicro-
bials, and can cause complications such as peritonsillar or retropharyngeal abscess, 
otitis, sinusitis, pneumonia, rheumatic fever, and post-streptococcal glomerulo-
nephritis [20]. Bacterial infections of the respiratory system can be located in the 
pharynx (pharyngotonsillitis). Viruses cause around 90% of pharyngitis, and 10% 
are caused by bacteria that have the vast majority associated with Streptococcus 
pyogenes or Beta-hemolytics of Lancefield group A (EBHGA) [21] however, other 
bacteria can cause pharyngotonsillitis such as Streptococcus mutans and Streptococcus 
pyogenes, Staphylococcus aureus, Moraxella catarrhalis, Haemophilus influenzae, 
Prevotella sp., Bacteroids fragilis, and Fusobacterium sp.
The diagnosis of EBHGA infection should preferably be confirmed microbio-
logically by rapid antigens detection tests and through oropharyngeal secretion 
culture. The gold standard for diagnosing oropharyngeal infections by EBHGA is 
culture [22], which should be done before starting treatment with antibiotics [23]. 
Clinical samples should be seeded on blood agar plates, which allows a preliminary 
screening of β-hemolytic colonies. Subsequent confirmation of suspected colonies 
such as EBHGA can be obtained by several laboratory tests, which are easily and 
quickly performed and which are still widely applied in clinical microbiology, 
despite the increasing use of automatic identification systems. EBHGA can be an 
oropharyngeal colonizing agent and thus, the microbiological investigation must 
be guided by clinical and epidemiological factors: patient’s age, clinical signs and 
symptoms, season, and personal exposure to EBHGA [24].
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According to the World Health Organization (WHO), approximately 600 million 
new pharyngotonsillitis cases due to EBHGA occur annually, and of these, 500 
thousand may progress with rheumatic fever and about 300 thousand with rheu-
matic carditis [25]. In developing countries, the occurrence is three times higher than 
in developed countries. The preliminary diagnosis and treatment of tonsillitis and 
pharyngitis is a common cause of inappropriate use of antibiotics.
Penicillin is the drug of choice for S. pyogenes infections’ empirical treatment, 
despite more than 60 years of use. S. pyogenes remains sensitive to penicillin, and 
resistance tests for penicillins or other beta-lactams approved for its treatment are 
unnecessary. However, more than 10% of patients report an allergy to penicillin, 
which leads to the use of cephalosporins, clindamycin, or macrolides as alternative 
treatments [26]. As rates of resistance to macrolides among isolated S. pyogenes have 
been increasing in North America and Europe, resistance tests for these substances 
may be indicated. Sore throat is a symptom that leading people to seek medical 
attention, and although it spontaneously remits, primary care doctors usually pre-
scribe antibiotics for it. In a systematic review, Spinks and collaborators concluded 
that antibiotics confer relative benefits in the treatment of sore throat. However, the 
absolute benefits are modest [27].
The research carried out at Santa Casa Hospital of São Carlos city (São Paulo, 
Brazil) by the CEPOF - Optics and Photonics Research Center” from University of 
São Paulo - São Carlos is composed of a clinical trial - “Turmeric and LED in the 
treatment of sore throat” with objectives as assessing the therapeutic efficacy of 
PDT with curcumin as an adjunct in the treatment of acute pharyngotonsillitis in 
adults in the municipality of São Carlos [28]. The photosensitizer used in this study 
was curcumin (0.75 mg/ml), using two minutes of illumination with a blue light 
(LED) at 450 nm. The clinical trial is randomized and controlled with adults aged 
18 to 45 years diagnosed with acute pharyngotonsillitis. Participants are undergoing 
a rapid test for the detection of group A beta-hemolytic streptococcus (EBHGA). 
Participants with streptococcal pharyngotonsillitis are divided into Antibiotic 
therapy comparison groups in conjunction with photodynamic therapy; and 
Antibiotic Therapy Group in conjunction with a photodynamic therapy placebo, 
and the therapeutic response will be evaluated in terms of clinical symptoms (sore 
throat and fever) and microbiological response, mainly considering the presence of 
EBHGA in the clinical response.
3.2  Designing antimicrobial-coating for endotracheal tube to prevent 
ventilator-associated respiratory tract infections
Mechanical ventilation (endotracheal intubation) is an effective intervention 
performed for breathing support in patients admitted in the intensive care unit, but it 
is also identified as one of the highest risk factors for developing ventilator-associated 
pneumonia (VAP) [29]. VAP is a type of nosocomial infection that results in a higher 
mortality (increase from 20–75%) and morbidity rate, prolonged lengths of hospi-
talization, and also increased hospitalization costs ($10,000 to $25,000) [30–32]. 
Furthermore, each year, approximately 50 million patients in the intensive care unit 
are intubated with an endotracheal tube (ETT) for breathing support worldwide [33].
Most cases of VAP are caused by the aspiration of infected (bacteria and/or 
virus) secretions from the oropharynx, although a small number of cases can result 
from direct bloodstream infection [34]. Moreover, there is a growing concern asso-
ciated with the ETT as the primary target related to VAP by biofilm formation on its 
surface [35]. Biofilms are characterized by its resistance to commercial antibiotics 
that favor resistant microorganisms’ proliferation and make them inaccessible to 
antimicrobials [36].
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Regarding VAP occur by ETT, aspiration occurs when there is distal migration 
of microorganisms present in the secretions accumulated above the ETT cuff. 
Moreover, biofilm is formed and attached in the lumen of ETT facilitating the 
transfer to the sterile bronchial tree [37], as presented in Figure 1.
Currently, there are methods used to prevent VAP based on its pathogenesis such 
as prevent aspiration of secretions and bacterial colonization of aerodigestive tract. 
Lastly, strategies include measures to minimize the risk of contaminated equipment 
but these methods show some practical limitations. In this regard, the development 
of strategies and new medical devices to avoid VAP is urgently need.
New medical devices based on the development of antimicrobial coated for ETT 
surface should be considered if they have been able to prevent VAP in well-designed 
clinical studies and be cost-effective [38]. Along the years, different strategies and 
antimicrobial coated for ETT surface (e.g. metal/antiseptics, metal/zeolites/d- -
tyrosine, nanorough/fructose, antimicrobial peptides, antibiotics/antiseptics, 
photo-based therapy, micropatterned surfaces, nanorough surfaces, and hydropho-
bic/hydrophilic) have been evaluated aiming to prevent the biofilm formation and 
VAP [38] (Figure 2).
These antimicrobial coated are functionalized on ETT surface via covalently or 
ionic bonding or creating a matrix on a polymer (e.g. polyvinyl chloride (PVC)) 
depending on the molecular structure of both antimicrobial and type of polymer-
based ETT and the presence of additives on ETT constitution [39].
As a selected example, in 2020, the Optics and Photonics Research Center from 
University of São Paulo developed a photo-based antimicrobial coating for ETT via 
functionalization of a natural product (curcumin) photosensitizer on PVC-based 
ETT surface [40] (Figure 3).
This therapeutic approach is based on the photoactivation of curcumin-
functionalized endotracheal tube using an optical fiber followed by the production 
of reactive oxygen species and 1O2 able to destroy biofilm and preventing its forma-
tion in the lumen of ETT. In this regard, the authors observed a photoelimination 
of bacteria biofilm such as E. coli (72%), S. aureus (95%), and P. aeruginosa (73%) 
previously formed on the ETT surface using a light dose of 50 J/cm2. Moreover, 
Figure 1. 
Pathogenesis of ventilator-associated pneumonia (VAP). Copyright (2020) National Academy of Sciences.
7
Antimicrobial Photodynamic Therapy of the Respiratory Tract: From the Proof of Principles…
DOI: http://dx.doi.org/10.5772/intechopen.95602
a prevention on formation of S. aureus bacteria biofilm in the lumen of curcumin-
functionalized endotracheal tube was observed when it was under illumination 
(at 450 nm, 35 mW/cm2) [39]. Furthermore, no degradation and leaching for 
curcumin-functionalized endotracheal tube under different pH values (2.0, 4.5, 
7.0, 8.0, and 10.0) were observed. These results pave the way for developing of 
photosensitizers-functionalized ETT and photodynamic action to combat hospital-
acquired infections like VAP [40].
Overall, the development and application of antimicrobials coatings for ETT have 
shown great promise and continue to progress. Significant results are being obtained 
with a wide family of the antimicrobial coating, including photosensitizers. From 
perspective, these in vitro methodologies developed so far could be applied in ex vivo 
and in vivo tests to evaluate and optimize these antimicrobial medical devices to be 
applied in clinical trials. In sum, this approach possesses excellent potential to reduce 
the number of deaths worldwide and decrease healthcare costs.
Figure 2. 
Antimicrobial coatings for ETT.
Figure 3. 
Curcumin-functionalized endotracheal tube. Copyright (2020) National Academy of Sciences.
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3.3 Lower respiratory tract infections and current treatment challenges
Lower respiratory infections are the fourth-largest cause of death worldwide 
and the main cause of death in low-income countries [14]. The most frequent lower 
respiratory infections are acute bronchitis and bronchiolitis, influenza, and pneu-
monia [41]. In Brazil, pneumonia is the number one cause of hospitalization [42]. It 
is also the main worldwide cause of death of children younger than 5 years old [43]. 
Although the number of hospitalizations has decreased over the past decades, the 
in-hospital mortality increased, mainly explained by the aging of the population 
and the occurrence of pneumonia cases that are more difficult to treat [42].
The European Respiratory Society defines pneumonia as an acute illness of 
the lower respiratory tract that includes cough and at least one other symptom: 
new focal chest signs, new lung shadowing shown by radiography, otherwise 
unexplained fever for more than 4 days, or otherwise unexplained tachypnea/
dyspnea [41]. Community Acquired Pneumonia (CAP) is contracted from contact 
with the infection in day-to-day life [41]. It is predominantly bacterial in origin, 
being Streptococcus pneumoniae its most prevalent pathogen [44]. Other important 
agents are Haemophilus influenza, Pseudomonas aeruginosa [44, 45]. Also, about 30% 
of cases are coinfections with viruses [46]. However, in the vast majority of CAP 
cases, there is no investigation of the etiological agent [42]. In such situations, the 
 treatment is based on the most prevalent microorganisms of that locality [42].
Hospital Acquired Pneumonia (HAP), also called nosocomial pneumonia, is 
the one that develops after at least 48 hours after the patients’ admission [47]. Its 
reported mortality rate ranges from 20 to 50%, the highest among nosocomial 
infections [47]. As mentioned above, ventilator-associated pneumonia (VAP) 
is the one contracted at least 48–72 hours after endotracheal intubation [41]. 
The most relevant HAP and VAP agents are also bacteria, like Staphylococcus 
aureus, Pseudomonas aeruginosa, Escherichia coli, and Klebsiella, Acinetobacter, and 
Enterobacter species [48]. Knowledge of the etiological agents is essential in treating 
these infections since patients who receive the wrong initial therapy have a high risk 
of mortality and morbidity [47]. However, the delay in starting the treatment also 
leads to poor prognostic [47]. A significant concern in HAP and VAP cases is the 
present of methicillin-resistant Staphylococcus aureus (MRSA), which is associated 
with elevated mortality rates and treatment costs [49]. Traditionally, the first-
choice drug for MRSA infections is vancomycin, which due to its low penetration in 
the lungs and high renal toxicity, leads to a failure rate the can reach 70% [49].
Even with new drugs like linezolid, tigecycline and ceftaroline, persists the diffi-
culty in increasing the success rate of treatments and the worry with the development 
of resistance [49, 50]. Linezolid, for example, was approved for clinical use in 2000, 
and cases of resistance in patients were reported as early as 2002 [51]. In a study from 
2014, the occurrence of non-susceptibility to this antibiotic remained relatively low, 
but several different resistance mechanisms had already been observed by then [51].
Another approach to hinder the burden of pneumonia is vaccination. Two types 
of vaccines are currently available for S. pneumoniae, the main agent in CAP: the 
pneumococcal polysaccharide vaccine (PPV) has been recommended for adults 
since the mid-1980’s, but it lacks efficacy in neonates and infants [52]; the pneumo-
coccal conjugate vaccines (PCVs), designed to overcome that, were first approved 
in 2000 [53]. However, pneumococcal vaccination faces two main challenges: first, 
each vaccine is only effective against the serotypes contained in it; second, the 
reduction of the said serotypes increases the colonization of other serotypes that 
are not covered by the vaccines, and of other pathogen species like S. aureus and 
H. influenza [52]. Thus, new vaccines need to be developed continuously, similarly 
to what happens to antibiotics [52].
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In face of so many challenges, PDT using indocyanine green (ICG) and infrared 
light has been studied in the treatment of bacterial pneumonia. ICG is a water-soluble 
dye that emits fluorescence when exposed to infrared light [54]. Its absorption peak 
in human plasma is 805 nm [55]. It is desirable to have the light excitation at this 
range because it penetrates deeper into biological tissue, since it is less absorbed by 
water, melanin and hemoglobin [56].
In an in vitro study by Leite et al., the in vitro inactivation of S. pneumoniae was 
effective using concentrations of ICG as low as 5 μM when combined with a 780 nm 
laser device or 10 μM when using an 850 nm LED. In these conditions, the treatment 
was safe for RAW 264.7 macrophages, and seemed to enhance their ability to fight 
the bacteria [57]. Other studies have also investigated similar protocols for other 
relevant pneumonia pathogens. Topaloglu et al. found an effective in vitro killing of 
S. aureus using 84 J/cm2 of light (809 nm) with 6 μg/mL of ICG, and of P. aeruginosa 
using 125 μg/mL ICG and 252 J/cm2 [58]. Kassab et al. had similar results for S. 
aureus, and showed that the same protocol, with up to 200 J/cm2 and 10 μM of ICG, 
was harmless to multiple mammalian cell lines [59].
The first in vivo investigation of the proposed protocol, performed by Geralde 
et al., found a reduction in the bacterial burden and an increase in the survival 
rate of SKH-1 hairless mice infected with S. pneumoniae after a single PDI session 
using ICG 100 μM and 120 J/cm2 of light at 780 nm, with a waiting interval of 
3 minutes [60]. In this study, the light exposure did not seem to be harmful to the 
animals. Additionally, the ICG alone was no different form the control, suggest-
ing that the activation with light was essential to the observed effects. It was then 
demonstrated that nebulization would be a viable delivery method for ICG to reach 
the lungs. ICG is compatible with air-jet nebulization in multiple concentrations, 
and it reaches and distributes in the lungs similarly as intranasal instillation [59, 61]. 
Additionally, mice exposed to pulmonary PDT using ICG and 216 J/cm2 of light at 
808 nm showed no clinical signs of toxicity or histological damage to the lungs, liver 
or stomach 7 days after the treatment [59]. Replicating such results in larger models 
and patients might be challenging due to the layers of biological tissue the light 
needs to go through to reach the target. Nonetheless, aPDT using ICG and infrared 
light shows good efficacy and safety in pre-clinical studies, and has great potential 
to become a treatment for lower respiratory infections.
4. Nanotechnology and future perspectives for aPDT
Antimicrobial Photodynamic Therapy is one of the main option that have been 
investigated against resistant bacteria. However, even with the use of some pho-
tosensitizers in the clinic, especially for tumor treatment and already approved by 
the FDA, some restrictions of these molecules, such as low solubility, little tissue 
penetration, low specificity and little accumulation in the target cells are some of 
the characteristics that hinders the greater use of this technique as the gold standard 
in various diseases [62] Nanotechnologies is one possibility to increase the efficacy 
of molecules with poor pharmacokinetics and pharmacodynamics properties, 
including PS [63].
Drug delivery is, therefore, one of the most challenges for aPDT [64]. For this 
reason, nanotechnology has been used in PDT as a possibility to increase its effect. 
Nano-systems can be stable (even under light), present good optical properties and 
high penetration in the tissue, as the skin (for topical application), have more speci-
ficity (with surface functionalization) and be more efficient in ROS production 
[62]. Nanomaterials can be used as PS itself or to load the PS (as carrier), opening 
several possibilities to conjugate nanotechnology with aPDT.
Photodynamic Therapy - From Basic Science to Clinical Research
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The nanoparticles used as drug carrier present some advantages in relation to 
traditional molecules, such as the transport in the blood circulation of hydrophobic 
substances, the incorporation of some antigen given them desired properties, the 
facility to enter in the target and yet, it is possible to control drug delivery [64]. 
Thus, several types of nanoparticles, with different sizes, shapes and functions, 
have been synthetized in the last years, including for aPDT [65]. They are classi-
fied according to their material: inorganic (as metal nanoparticles), organic (as 
 liposomes) and nanocomposites, organic or inorganic [66].
Some nanomaterials have been explored under irradiation, showing photody-
namic effect and have been applied in different tests. Gold and Silver nanoparticles, 
nanomaterials based in silica and silicon, quantum-dots, carbon-based materials 
and nanoparticles from organic molecules are examples of the materials already 
used in photodynamic therapy and its multimodal conjugation treatments in several 
application [62].
The nanosystems also enable the delivery of PS with desirable optical character-
istics, such as the use of absorption by two photons or upconversion nanoparticles 
and can result in high penetration into the tissue. Thus, they can be activated from 
X-ray to infrared, reaching regions of the body that previously were not possible 
with traditional PDT. This prospect of applying nano PDT can make this technique 
extremely useful in the context of respiratory diseases, especially due to the current 
concern about infections caused by resistant bacteria, the pandemic of the corona-
virus, or the next outbreaks that are yet to come [64].
However, it is still necessary to overcome the barrier between in vitro and in vivo 
studies to reach nanotechnology’s clinical applications. Viral, fungal and bacterial 
infections characterize a global public health problem and, with the coronavirus 
pandemic, humanity saw the urgency to invest in new therapeutic possibilities, 
especially because new pandemics have been predicted. The advent of nanotechnol-
ogy has helped to provide quick answers to urgent problems [63]. The scientific and 
clinical community’s joint efforts and their integration into industry are needed to 
respond quickly to respiratory diseases [67].
APDT is increasingly becoming a viable option for upper and lower airway 
infections and nanosystems can help to break traditional PDT barriers. The search 
for highly efficient PS has been one of the main research lines when it comes to 
improving PDT. Many molecules synthesis methods have been explored, as well as 
the synthesis of nanoparticles, but they are usually complicated and, especially with 
nanoparticles, are difficult to apply for large-scale production. Thus, simpler synthe-
sis methods with functionalization of these nanometric systems have been gaining 
relevance in the scientific community, since it is one of the challenges for the clinical 
implementation of nano-PDT [68]. It is also necessary to understand the parameters 
beyond the laboratory, such as dose, irradiation and clinical efficacy [69].
5. Conclusions
Increased resistance to antibiotics has a direct impact on humanity and is one 
of the most important public health problems worldwide. Especially in the respira-
tory tract (lower and upper), which involves pharyngotonsillitis, pneumonia and 
infections by endotracheal tube, new therapeutic possibilities are needed. APDT 
has been shown to be highly effective against the microorganisms that cause these 
diseases and several protocols with different photosensitizers and illumination 
devices have been developed to make aPDT a great therapeutic option. New mol-
ecules and nanotechnology have been developed to improve aPDT and break down 
barriers to clinical applications.
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